

Request under Freedom of Information Act 2000

Request Ref: NGFOI 17/18: 433

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 20/12/17.

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the conditions listed below.

- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Psoriasis
- Hidradenitis Suppurativa
- Crohn's disease
- Ulcerative Colitis

I am pleased to be able to provide you with the following information.

These are the figures for the last 12 months ending 30/11/17.

| Number of patients treated | Rheumatoid Arthritis | Ankylosing Spondylitis | Psoriatic Arthritis | Psoriasis | Hidradenitis Suppurativa | Crohn's disease | Ulcerative Colitis |
|--------------------------------|-------------------------|---------------------------|------------------------|-----------|-----------------------------|-----------------|-----------------------|
| TOTAL | | | | | | | |
| Abatacept [Orencia] | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adalimumab [Biosimilar] | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adalimumab [Humira] | 72 | 37 | 39 | 20 | 1 | 63 | 12 |
| Apremilast [Otezla] | 0 | 0 | 21 | 9 | 0 | 0 | 0 |
| Baricitinib [Olumiant] | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Brodalumab [Kyntheum] | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Certolizumab [Cimzia] | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dimethyl fumarate [Skilarence] | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Etanercept [Enbrel] | 25 | 3 | 7 | 3 | 0 | 0 | 0 |
| Etanercept Biosimilar | 128 | 40 | 41 | 11 | 0 | 0 | 0 |

| [Benepali or Erelzi] | | | | | | | |
|---|----|----|----|----|---|----|----|
| Golimumab [Simponi] | 17 | 11 | 18 | 0 | 0 | 0 | 2 |
| Guselkumab [Tremfya] | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infliximab [Remicade] | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Infliximab Biosimilar [Inflectra, Remsima or Flixabi] | 6 | 1 | 1 | 0 | 0 | 63 | 27 |
| Ixekizumab [Taltz] | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rituximab [Mabthera] | 56 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rituximab Biosimilar [Rixathon or Truxima] | 40 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sarilumab [Kevzara] | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Secukinumab [Cosentyx] | 0 | 9 | 0 | 6 | 0 | 0 | 0 |
| Tocilizumab [Ro Actemra] | 36 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tofacitinib [Xeljanz] | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ustekinumab [Stelara] | 0 | 0 | 4 | 23 | 0 | 0 | 0 |
| Vedolizumab [Entyvio] | 0 | 0 | 0 | 0 | 0 | 9 | 22 |